Brief Articles
toimidazole, thiouracil, and propylthiouracil in vitro and its relationship
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 22 7317
iodine: the isolation of two unusual ionic compounds derived from
Se-methimazole. Org. Biomol. Chem. 2006, 4, 2883–2887. (d) Roy,
G.; Das, D.; Mugesh, G. Bioinorganic chemistry aspects of the
inhibition of thyroid hormone biosynthesis by antihyperthyroid drugs.
Inorg. Chim. Acta 2007, 360, 303–316. (e) Roy, G.; Mugesh, G.
Selenium analogues of antithyroid drugssrecent developments. Chem.
BiodiVersity 2008, 5, 414–439.
to in vivo findings. Endocrinology 1978, 103, 871–882. (c) Engler,
H.; Taurog, A.; Luthy, C.; Dorris, M. L. Reversible and irreversible
inhibition of thyroid peroxidase-catalyzed iodination by thioureylene
drugs. Endocrinology 1983, 112, 86–95. (d) Shiroozu, A.; Taurog,
A.; Engler, H.; Dorris, M. L. Mechanism of action of thioureylene
antithyroid drugs in the rat: possible inactivation of thyroid peroxidase
by propylthiouracil. Endocrinology 1983, 113, 362–370.
(7) Bourissou, D.; Guerret, O.; Gabba¨ı, F. P.; Bertrand, G. Stable carbenes.
Chem. ReV. 2000, 100, 39–91, and references therein.
(3) It has been reported that PTU, but not MMI, also inhibits the
selenocysteine-containing enzyme iodothyronine deiodinase (ID),
which catalyzes the monodeiodination of the prohormone thyroxine
(T4) to its biologically active form T3. For details, see: (a) Ko¨hrle, J.
The trace element selenium and the thyroid gland. Biochimie 1999,
81, 527–533. (b) du Mont, W.-W.; Mugesh, G.; Wismach, C.; Jones,
P. G. Reactions of organoselenenyl iodides with thiouracil drugs: an
enzyme mimetic study on the inhibition of iodothyronine deiodinase.
Angew. Chem., Int. Ed. 2001, 40, 2486–2489. (c) Bianco, A. C.;
Salvatore, D.; Gereben, B.; Berry, M. J.; Larsen, P. R. Biochemistry,
cellular and molecular biology, and physiological roles of the
iodothyronine selenodeiodinases. Endocr. ReV. 2002, 23, 38–89. (d)
Ko¨hrle, J. Iodothyronine deiodinases. Methods Enzymol. 2002, 347,
125–167.
(8) (a) Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.
Completion and refinement of crystal structures with SIR92. J. Appl.
Crystallogr. 1993, 26, 343–350. (b) Sheldrick, G. M. Phase annealing
in SHELX-90: direct methods for larger structures. Acta Crystallogr.
Sect. A: Found. Crystallogr. 1990, 46, 467–473. (c) Sheldrick, G. M.
SHELX-97, Program for the Refinement of Crystal Structures;
University of Go¨ttingen: Go¨ttingen, Germany, 1997; CCDC-693450
(for compound 5), CCDC-693451 (for compound 15), CCDC-693452
(for compound 20), CCDC-693453 (for compound 14), and CCDC-
693454 (for compound 6) contain the supplementary crystallographic
data for this paper. These data can be obtained free of charge from
data_request/cif.
(4) (a) Nakashima, T.; Tourog, A. Rapid conversion of carbimazole to
methimazole in serum; evidence for an enzymatic mechanism. Clin.
Endocrinol. 1979, 10, 637–648. (b) Jansson, R.; Dahlberg, P. A.;
Lindstro¨m, B. Comparative bioavailability of carbimazole and me-
thimazole. Int. J. Clin. Pharmacol. Ther. Toxicol. 1983, 21, 505–510.
(5) (a) Visser, T. J.; Kaptein, E.; Aboul-Enein, H. Y. Selenoracil
derivatives are potent inhibitors of the selenoenzyme type I iodothy-
ronine deiodinase. Biochem. Biophys. Res. Commun. 1992, 189, 1362–
1367. (b) Aboul-Enein, H. Y.; Awad, A. A.; Al-Andis, N. M. Synthesis
and the antiperoxidase activity of seleno analogues of the antithyroid
drug propylthiouracil. J. Enzyme. Inhib. 1993, 7, 147–150. (c) Guziec,
L. J.; Guziec, F. S. Jr. A directed metalation route to the selenium
analog of methimazole. J. Org. Chem. 1994, 59, 4691–4692. (d)
Taurog, A.; Dorris, M. L.; Guziec, L. J.; Guziec, F. S., Jr. The selenium
analog of methimazole. Measurement of its inhibitory effect on type
I 5′-deiodinase and of its antithyroid activity. Biochem. Pharmacol.
1994, 48, 1447–1453. (e) Taurog, A.; Dorris, M. L.; Hu, W.-X.;
Guziec, F. S. Jr. The selenium analog of 6-propylthiouracil. Measure-
ment of its inhibitory effect on type I iodothyronine deiodinase and
of its antithyroid activity. Biochem. Pharmacol. 1995, 49, 701–709.
(f) Landry, V. K.; Minoura, M.; Pang, K.; Buccella, D.; Kelly, B. V.;
Parkin, G. Synthesis and structural characterization of 1-mesityl-1,3-
dihydro-imidazole-2-selone and bis(1-mesitylimidazol-2-yl)diselenide:
experimental evidence that the selone is more stable than the selenol
tautomer. J. Am. Chem. Soc. 2006, 128, 12490–12497. (g) Antoniadis,
C. D.; Hadjikakou, S. K.; Hadjiliadis, N.; Papakyriakou, A.; Baril,
M.; Butler, I. S. Synthesis and structures of Se analogues of the
antithyroid drug 6-n-propyl-2-thiouracil and its alkyl derivatives:
formation of dimeric Se-Se compounds and deselenation reactions
of charge-transfer adducts of diiodine. Chem.sEur. J. 2006, 12, 6888–
6897.
(9) All the calculations were carried out by using the Gaussian suite of
quantum chemical programs. Frisch, M. J.; Trucks, G. W.; Schlegel,
H. B.; Scusera, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski,
V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.;
Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain,
M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.;
Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.;
Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.;
Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.;
Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.;
Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-
Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challa-
combe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.;
Andres, J. L.; Gonzale, C.; Head-Gordon, M.; Replogle, E. S.; Pople,
J. A. Gaussian 98, revision A 11.3; Gaussian, Inc.; Pittsburgh, PA,
1998.
(10) (a) Reed, A. E.; Curtiss, L. A.; Weinhold, F. Intermolecular interactions
from a natural bond orbital, donor-acceptor viewpoint. Chem. ReV.
1988, 88, 899–926. (b) Glendening, E. D.; Reed, J. E.; Carpenter,
J. E.; Weinhold, F. Natural Bond Orbital (NBO), version 3.1.
(11) (a) Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti
correlation-energy formula into a functional of the electron density.
Phys. ReV. B 1988, 37, 785–789. (b) Becke, A. D. Density-functional
thermochemistry. III. The role of exact exchange. J. Chem. Phys. 1993,
98, 5648–5652.
(12) The enzyme inhibition experiments were carried out with Fe-containing
lactoperoxidase (LPO) because it is readily available in purified form.
Furthermore, LPO has been shown to behave very similarly to TPO
with respect to iodination of thyroglobulin, the natural substrate, and
other iodide acceptors. Taurog, A.; Dorris, M. L.; Lamas, L.
Comparison of lactoperoxidase- and thyroid peroxidase-catalyzed
iodination and coupling. Endocrinology 1974, 94, 1286–1294.
(13) The hydrolysis of N-C bond in assay mixture was confirmed by HPLC
analysis. The initial rates for the hydrolysis of N-C bond in various
thiones/selones are given in Supporting Information, (Page S18).
(6) (a) Roy, G.; Nethaji, M.; Mugesh, G. Biomimetic studies on antithyroid
drugs and thyroid hormone synthesis. J. Am. Chem. Soc. 2004, 126,
2712–2713. (b) Roy, G.; Mugesh, G. Antithyroid drugs and thyroid
hormone synthesis: effect of methimazole derivatives on peroxidase-
catalyzed reactions. J. Am. Chem. Soc. 2005, 127, 15207–15217. (c)
Roy, G.; Nethaji, M.; Mugesh, G. Interaction of antithyroid drugs with
JM800894M